Trifluoroacetic acid → 4-(4-Amino-quinazolin-7-ylmethyl)-2-(S)-methoxymethyl-3-oxo-piperazine-1-carboxylic acid (4-chloro-phenyl)-amide
Reaktionsgleichung
[NH2:1][C:2]1[C:11]2[C:6](=[CH:7][C:8]([CH2:12][N:13]3[CH2:18][CH2:17][NH:16][CH:15]([CH2:19][O:20][CH3:21])[C:14]3=[O:22])=[CH:9][CH:10]=2)[N:5]=[CH:4][N:3]=1.[Cl:23][C:24]1[CH:29]=[CH:28][C:27]([N:30]=[C:31]=[O:32])=[CH:26][CH:25]=1.C(O)(C(F)(F)F)=O>>[Cl:23][C:24]1[CH:29]=[CH:28][C:27]([NH:30][C:31]([N:16]2[CH2:17][CH2:18][N:13]([CH2:12][C:8]3[CH:7]=[C:6]4[C:11]([C:2]([NH2:1])=[N:3][CH:4]=[N:5]4)=[CH:10][CH:9]=3)[C:14](=[O:22])[C@@H:15]2[CH2:19][O:20][CH3:21])=[O:32])=[CH:26][CH:25]=1Komponenten
4
Versuchsvorschrift
The title compound is prepared as described in EXAMPLE 436 using 1-(4-amino-quinazoline-7-ylmethyl)-3-methoxymethyl-piperazine-2-one, EXAMPLE 75, and 4-chlorophenyl isocyanate. 1H NMR (DMSO-d6, 300 MHz) δ9.77 (bs, 2H), 8.81 (s, 1H), 8.70 (s, 1H), 8.40 (d, 1H), 7.64 (d, 1H), 7.61 (s, 1H), 7.49 (d, 2H), 7.28 (d, 2H), 4.88 (m, 1H), 4.80 (AB, 2H), 4.19 (m, 1H), 3.96 (m, 1H), 3.74-3.42 (m, 4H), 3.28 (s, 3H). ESI MS, [M+H]+=455,457 (Cl pattern). Anal. (C22H23ClN6O3.TFA.1.5H2O) C, H, N.
Quellen und Nachweise
- ORD-Eintrag
- ord-b6ef8c62420c4e4792e3289df1f143d5
- Quelldatensatz
- uspto-grants-2009_11
- Patentnummer
- US07612075B2
Notizen zur Reaktion
Wird geladen…